AS Brett
Abstract
Two inhibitors of tumor necrosis factor (TNF) -- etanercept (Enbrel), which binds to TNF, and infliximab (Remicade), a monoclonal antibody against TNF -- now are available for treatment of rheumatoid arthritis (RA). Findings from 2 large trials, funded by the drugs' manufacturers, add to the existing data. In one study, 632 patients with early …
OpenAlex reports 2 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Two inhibitors of tumor necrosis factor (TNF) -- etanercept (Enbrel), which binds to TNF, and infliximab (Remicade), a monoclonal antibody against TNF -- now are available for treatment of rheumatoid arthritis (RA). Findings from 2 large trials, funded by the drugs' manufacturers, add to the existing data. In one study, 632 patients with early …
Key concepts: Etanercept, Rheumatoid arthritis, Infliximab, Medicine, Tumor necrosis factor alpha, Monoclonal antibody, TNF inhibitor, Tumor necrosis factor α